What is AssayQuant Technologies?
AssayQuant Technologies, Inc. operates at the intersection of advanced biochemistry and pharmaceutical research, specializing in continuous kinase and phosphatase assays. The company's core value proposition lies in its proprietary PhosphoSens technology, which provides real-time, high-fidelity measurements of enzyme activity. This capability is essential for researchers aiming to understand complex inhibitor mechanisms and enzyme behavior during the early stages of drug development.
By offering a comprehensive suite of assay kits alongside custom profiling services, the company serves as a vital partner for pharmaceutical and biotechnology firms. Their solutions are engineered to enhance decision-making processes, effectively reducing the time and cost associated with target validation and lead optimization. As the industry shifts toward more data-intensive research methodologies, AssayQuant's focus on kinetic precision positions it as a leader in the analytical tools market.
How much funding has AssayQuant Technologies raised?
AssayQuant Technologies has raised a total of $115K across 1 funding round:
Debt
$115K
Debt (2021): $115K with participation from PPP
Key Investors in AssayQuant Technologies
PPP
Public-Private Partnership
What's next for AssayQuant Technologies?
Looking ahead, the strategic deployment of this capital will likely focus on the commercial expansion of the PhosphoSens platform and the diversification of the company's assay portfolio. As AssayQuant Technologies navigates this late-stage growth phase, the focus will shift toward deepening its integration into the workflows of major global pharmaceutical entities. The company is expected to prioritize the scaling of its custom assay development services to meet the rising demand for specialized, high-throughput screening solutions.
Furthermore, the firm is poised to leverage its current financial stability to explore new therapeutic areas, potentially extending its kinetic insights into broader enzyme classes. By maintaining its commitment to technical excellence and research-driven innovation, AssayQuant Technologies is set to maintain its competitive edge, ensuring that its analytical tools remain the gold standard for preclinical drug discovery programs worldwide.
